LFWD — Lifeward Ltd.

Summary of Lifeward Ltd. Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue: Lifeward reported Q3 2025 revenue of $6.2 million, a slight increase of 1.1% year-over-year and an 8% increase from Q2 2025.
• Product Breakdown: Revenue from traditional products (ReWalk, MyoCycle, ReStore) was $3.1 million (up 24% YoY), while revenue from ATLAS G products was $3.1 million (down from $3.6 million YoY).
• Gross Profit: GAAP gross profit was $2.7 million (43.7% of revenue), up from $2.2 million (36.2% of revenue) in Q3 2024.
• Operating Loss: GAAP operating loss was $3.1 million, slightly improved from $3.2 million in the prior year. Non-GAAP operating loss was $3 million, down from $4.1 million YoY.
• Cash Position: Ended the quarter with $2 million in cash and cash equivalents, with a $3 million loan secured from Oramed to bolster liquidity.

2. Strategic Updates and Business Highlights

• Operational Efficiencies: Achieved a 16% reduction in quarterly cash burn and a 27% reduction in non-GAAP operating loss.
• Market Expansion: Secured CE Mark approval for ReWalk 7, expanding access to the European market, which is estimated to represent 40% of the global addressable exoskeleton market.
• Sales Growth: Notable increase in ReWalk placements among Medicare beneficiaries, with a pipeline of over 117 qualified leads in the U.S. and 49 in Germany.
• Partnerships: Ongoing collaboration with CoreLife is expected to enhance patient access and sales pipeline growth.

3. Forward Guidance and Outlook

• Lifeward reaffirmed its full-year 2025 revenue guidance of $24 million to $26 million, anticipating a 21% growth from Q3 figures.
• Projected non-GAAP net loss for the year is estimated to be between $12 million and $14 million.

4. Bad News, Challenges, or Points of Concern

• Decline in ATLAS G Revenue: Revenue from ATLAS G products decreased, attributed to timing factors and quarterly revenue mix.
• Operational Focus: Need for sharper operational focus and discipline was highlighted, indicating previous inefficiencies.
• Market Competition: Concerns about competitive pressures and the need to establish strong channel partnerships for sustained growth were discussed.

5. Notable Q&A Insights

• The company confirmed that all 33 active rentals of ReWalk units were in Germany, indicating strong market penetration.
• The CEO emphasized the importance of channel management and payer access as critical to future growth.
• Questions regarding the sustainability of the recent Medicare sales growth were met with optimism, citing a focused sales strategy and existing backlog.
• The company is exploring opportunities in the sports arena, which may primarily involve self-pay models, but also noted government support for their products.

This earnings call reflects Lifeward Ltd.'s ongoing transformation efforts, with a focus on operational efficiency and market expansion, while also addressing challenges related to product revenue fluctuations and competitive dynamics.